The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the “Greed” zone on Tuesday.U.S. stocks settled higher on Tuesday, with the S&P 500 settling at a record level during the session amid a surge in artificial intelligence names.The New York Stock Exchange will close at 1 p.m. ET on Wednesday and will be closed on Thursday for Christmas Day.Gross domestic product expanded at a 4.3% annualized pace in the third quarter, beating estimates n ...

for more in its first ever GLP1 pill. Guggenheim partner Sheamus Fernandez joins us now. He is the firm's managing director and pharma analyst.Sheamus, great to have you with us. >> Nice to see you. >> Does this change the competitive landscape at all with Eli Liy's or four coming on um and and some other competitors coming, you know, down the pike.>> It's a great question. I mean, I think it doesn't necessarily change the competitive landscape that dramatically. Um but it does give Novo an opportunity to g ...

Core Insights - Novo Nordisk is entering the oral GLP-1 market with its new pill, which may provide an opportunity to gain market share despite not dramatically changing the competitive landscape [2][3] - The success of Novo's pill will depend on its manufacturing capabilities and the ability to meet demand, as the active ingredient requires significantly more quantity compared to injectables [4][5][6] - Consumer preferences will be tested in 2026, determining whether they favor the convenience of a pill over the effectiveness of injectables [7][8][9] Manufacturing and Supply - Novo has begun manufacturing the active ingredient for its pill in North Carolina, but there are concerns about its ability to meet demand due to the complexity of the molecule [4][5] - The pill formulation requires approximately 70 times more of the active ingredient to be effective compared to injectable forms, which poses additional manufacturing challenges [6] Market Dynamics - The introduction of Novo's pill and Eli Lilly's upcoming orforglipron will create a competitive environment where consumer preferences will play a crucial role [3][7] - Eli Lilly has demonstrated effective marketing strategies with its own products, which may influence consumer choices in the market [8][9]

Core Insights - The total addressable market for GLP-1 pills is significant, with over 100 million Americans affected by obesity, indicating a large potential user base for these medications [2][3] - The transition from injectable to oral forms of GLP-1 drugs is expected to increase accessibility and adoption among patients who dislike injections, potentially leading to a higher uptake of these treatments [2][3] Market Dynamics - Novo Nordisk is currently leading the market with its GLP-1 drug, while Eli Lilly is expected to follow closely behind, likely launching its product a few months later [3][4] - The competitive landscape is characterized by a rush to enroll patients before Eli Lilly's product becomes available, as established users may be reluctant to switch medications once they start seeing results [4] Efficacy and Health Impact - Both Novo Nordisk and Eli Lilly's drugs are anticipated to be effective in promoting weight loss and improving related health conditions, with Eli Lilly's product potentially offering slightly better results [5] - A significant increase in the number of users, particularly among those who avoid injections, could lead to improved health outcomes and potentially lower healthcare costs in the long term, despite initial higher expenses associated with these drugs [5][7] Long-term Outlook - The initial phase may see increased healthcare costs due to the high price of these medications, but the long-term health benefits could lead to improved longevity and overall health for the population [6][7] - The focus of these drugs is primarily on health improvement rather than cost reduction, emphasizing the importance of enhancing quality of life and longevity for users [8]

Wage Garnishments for Defaulted Student Loans to Begin Early Next Year 48 minutes ago Months after being originally announced, defaulted federal student loan borrowers will have their wages cut by the Department of Education early next year. Since this summer, the Department of Education has said it will garnish wages from borrowers who have defaulted on their loans. On Jan. 7, the first batch of defaulted borrowers, approximately 1,000, will be notified that their wages are set to be garnished, the Departm ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday.The Dow traded up 0.22% to 48,469.41 while the NASDAQ rose 0.40% to 23,521.69. The S&P 500 also rose, gaining, 0.34% to 6,901.90.Check This Out: Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For TuesdayLeading and Lagging SectorsCommunication services shares rose by 0.5% on Tuesday.In trading on Tuesday, consumer staples stocks fell by 0.5%.Top HeadlineU.S. durable goods orders decl ...

Key Takeaways NVO's Wegovy pill becomes the first oral GLP-1 for obesity and plans a U.S. launch in early January 2026.FDA approved NVO's once-daily oral Wegovy to cut excess weight, maintain loss and reduce cardiovascular risk.Novo Nordisk's OASIS 4 study showed 16.6% mean weight loss, with one in three patients losing 20% or more.Novo Nordisk (NVO) announced the FDA approval of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and ...

I was losing hope regarding the oral semaglutide (aka Wegovy pill) gaining FDA approval, but the positive outcome came right before Christmas. I personally think this is the turning point for Novo Nordisk A/S (Hi there, welcome to my profile. My name is Eugenio Catone, I live in Italy and I am 27 years old.In 2023 I graduated in Business Administration and I completed CFA level 1 in 2024. I am currently a Popular Investor on the investing platform eToro, you can see there my public portfolio. My interest in ...

U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Tuesday.Shares of Novo Nordisk A/S (NYSE:NVO) rose sharply during Tuesday's session following FDA approval of its Wegovy pill.Novo Nordisk received approval from the U.S. Food and Drug Administration for its GLP-1 pill, marking the first approval of its kind globally.Novo Nordisk shares jumped 8.6% to $52.26 on Tuesday.Here are some other big stocks recording gains in today’s session.WW International Inc (NASDAQ:WW) shares jumped 14.4% ...

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...